Your session is about to expire
← Back to Search
Plerixafor for Sickle Cell Disease (PISMO Trial)
PISMO Trial Summary
This trial is testing if two doses of a medication called plerixafor is a safe and effective way to get enough healthy blood cells for a transplant in people with sickle cell disease.
PISMO Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2021 Phase 2 & 3 trial • 20 Patients • NCT02231879PISMO Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have never received gene therapy.I have sickle cell disease with a specific genetic makeup.I am able to care for myself but may not be able to do active work.I do not have any ongoing serious infections.I haven't taken G-CSF or plerixafor in the last 4 weeks.My kidneys work well, with a filtration rate of at least 60 ml/min.I have had a stroke or neurological issue lasting more than a day, confirmed by an MRI.I have had at least one episode of acute chest syndrome despite treatment.I've had regular blood transfusions (at least 8 a year) for over a year to prevent complications.My liver is functioning within the required limits.I have bone damage in two or more of my joints.My heart pumps well, with an ejection fraction over 50%.I agree to use effective birth control or practice abstinence during the study.I have a known bone marrow disorder.I've had 2 or more severe pain crises needing hospital care in the last year.I have had a stroke or neurological issue lasting more than a day.I have not had major surgery in the last 30 days.I've had 2 or more severe pain crises needing hospital care in the last 2 years.I do not have any serious infections needing major treatment.I have been diagnosed with pulmonary hypertension through a heart catheter test.I have been diagnosed with alpha thalassemia.I have been cancer-free for 5 years, except for treated skin cancer.I have had a bone marrow harvest within the last year.
- Group 1: Plerixafor
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What is the current cohort size for this research project?
"Affirmative. Clinicaltrials.gov records that this trial is in the midst of recruiting participants, having been published on September 19th 2018 and edited most recently on February 17th 2022. The researchers are looking for 12 individuals at a single site."
Are recruitment efforts ongoing for this clinical trial?
"Affirmative. Information posted on clinicaltrials.gov shows that this research trial, which was first published on September 19th 2018, is currently seeking volunteers. The study requires 12 participants to be recruited from 1 medical facility."
What risks should patients be aware of when taking Plerixafor?
"As this is an early phase medical trial, the safety of Plerixafor has been rated as a 1 due to limited clinical data validating its efficacy and ensuring it is safe."
Are minors within the parameters of this experiment?
"According to the specified requirements of this trial, eligible candidates must be aged between 18 and 40."
Could you provide a synopsis of research done involving Plerixafor?
"At the moment, there are 18 ongoing investigations of Plerixafor in action, none reaching Phase 3. 54 different medical centres across America are participating in these studies, with a high concentration located in Seattle, Washington."
What type of participant would be best suited for this research project?
"12 individuals are being admitted to this investigation, but they must meet the criteria of having anemia and sickle cell disorder while also falling within 18-40 years old."
Share this study with friends
Copy Link
Messenger